Incyte

ABOUT

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.

Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients and make a difference in healthcare. Incyte’s unique expertise in medicinal chemistry and biology has enabled us to establish a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity, including 24 clinical compounds in development.

Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. We have more than 2,500 employees, including more than 1,000 world-class scientists, who are committed to discovering first-in-class medicines for patients who previously had limited treatment options.

For more information about Incyte, please visit us at www.Incyte.com. Follow Incyte on X, LinkedIn, Facebook and Instagram.

1801 Augustine Cut-off, Wilmington, DE 19803
NEWS
FDA
Incyte had a particularly big week scheduled with the U.S. FDA, which included two PDUFA dates and an advisory committee meeting. In addition, Ascendis had a target action date.
It was another busy week for clinical trial announcement. Here’s a look.
Companies have already begun their announcements of new clinical studies for various treatment settings in preparation for ASCO 2021.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 13, 2021.
It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more.
Eli Lilly and Company and Incyte announced today that their Phase III COV-BARRIER study of Olumiant (baricitinib) plus standard of care (SoC) compared to placebo plus SoC failed to hit statistical significance against COVID-19 for its primary endpoint.
The action data was extended by the agency to provide more time to review new data analyses submitted by Lilly, per information requests made by the FDA.
The topline data from the BRAVE-AA2 study in 546 adults showed both 2 mg and 4 mg doses of Olumiant regrew hair in adult patients with more than 50% scalp hair loss, compared with placebo.
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
AWARDS
  • 2025 BPTW Badge - RBG.png
JOBS
IN THE PRESS